Primary non-adherence to anti-dementia drugs, antidepressants, antipsychotics and benzodiazepines in individuals with dementia in Germany: A cohort study of primary care prescriptions

Background Individuals with dementia frequently receive psychotropic and anti-dementia medication. Primary non-adherence (PNA), the failure to dispense a newly initiated medication, is an early and overlooked treatment barrier. Objective To estimate PNA at treatment initiation across four medication classes in dementia, to analyse subsequent prescriptions separately, and to identify associated patient factors. Methods Retrospective cohort study using German primary care records linked to pharmacy dispensing data. Individuals aged 65 years and older with dementia who initiated anti-dementia drugs, antidepressants, antipsychotics, or benzodiazepines and related sedatives in general practices were included. Treatment initiation required 365 days of prior observation and no dispensing of the same class in that period. PNA was defined as failure to dispense within 30 days. Generalized estimating equations accounted for repeated observations within patients. Results Among 10,746 initiations from 8634 individuals (mean age 83.4 years; 64.3% women), PNA occurred in 13.4% (95% CI 11.8–15.1) of anti-dementia drug, 11.5% (10.2–12.9) of antidepressant, 8.7% (7.9–9.5) of antipsychotic and 25.7% (23.8–27.7) of benzodiazepine initiations. Compared with antipsychotics, odds were higher for anti-dementia drugs (OR 1.54; 1.30–1.82), antidepressants (1.29; 1.11–1.51) and benzodiazepines (3.63; 3.14–4.20). Results were homogeneous across age cohorts (interaction p = 0.97). Among 180,796 subsequent prescriptions, non-dispensing was lower than at initiation except for benzodiazepines (31.5%). Conclusions PNA at initiation was moderate for anti-dementia drugs, antidepressants and antipsychotics, and considerably higher for benzodiazepines and related sedatives. The latter warrants investigation into access barriers, preferences, safety concerns, and incomplete capture of privately issued prescriptions.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-11-14
DOI
https://doi.org/10.1177/13872877261507606
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary non-adherence to anti-dementia drugs, antidepressants, antipsychotics and benzodiazepines in individuals with dementia in Germany: A cohort study of primary care prescriptions

Jens Bohlken, Karel Kostev, Steffi Gerlinde Riedel-Heller
Journal of Alzheimer s Disease
Medication Adherence and Compliance
article

Primary non-adherence to anti-dementia drugs, antidepressants, antipsychotics and benzodiazepines in individuals with dementia in Germany: A cohort study of primary care prescriptions

Jens Bohlken, Karel Kostev, Steffi Gerlinde Riedel-Heller
article en

Abstract

Background Individuals with dementia frequently receive psychotropic and anti-dementia medication. Primary non-adherence (PNA), the failure to dispense a newly initiated medication, is an early and overlooked treatment barrier. Objective To estimate PNA at treatment initiation across four medication classes in dementia, to analyse subsequent prescriptions separately, and to identify associated patient factors. Methods Retrospective cohort study using German primary care records linked to pharmacy dispensing data. Individuals aged 65 years and older with dementia who initiated anti-dementia drugs, antidepressants, antipsychotics, or benzodiazepines and related sedatives in general practices were included. Treatment initiation required 365 days of prior observation and no dispensing of the same class in that period. PNA was defined as failure to dispense within 30 days. Generalized estimating equations accounted for repeated observations within patients. Results Among 10,746 initiations from 8634 individuals (mean age 83.4 years; 64.3% women), PNA occurred in 13.4% (95% CI 11.8–15.1) of anti-dementia drug, 11.5% (10.2–12.9) of antidepressant, 8.7% (7.9–9.5) of antipsychotic and 25.7% (23.8–27.7) of benzodiazepine initiations. Compared with antipsychotics, odds were higher for anti-dementia drugs (OR 1.54; 1.30–1.82), antidepressants (1.29; 1.11–1.51) and benzodiazepines (3.63; 3.14–4.20). Results were homogeneous across age cohorts (interaction p = 0.97). Among 180,796 subsequent prescriptions, non-dispensing was lower than at initiation except for benzodiazepines (31.5%). Conclusions PNA at initiation was moderate for anti-dementia drugs, antidepressants and antipsychotics, and considerably higher for benzodiazepines and related sedatives. The latter warrants investigation into access barriers, preferences, safety concerns, and incomplete capture of privately issued prescriptions.

Journal of Alzheimer s Disease
Philipps University of Marburg (DE), Universitätsklinikum Gießen und Marburg (DE), IQVIA (United Kingdom) (GB), Leipzig University (DE)
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon